A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects With Immunoglobulin A Nephropathy (IgAN)

Trial Profile

A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects With Immunoglobulin A Nephropathy (IgAN)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs SM 101 (Primary)
  • Indications IgA nephropathy
  • Focus Therapeutic Use
  • Sponsors Baxalta; Shire
  • Most Recent Events

    • 03 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
    • 20 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top